The Importance of Early Diagnosis and Treatment in Obstructive HCM

In The Importance of Early Diagnosis and Treatment in Obstructive HCM, our experts delve into the following critical questions:

Can you please describe why it is important to diagnose obstructive HCM and the importance of history taking?

What are the treatment recommendations for patients with obstructive hypertrophic cardiomyopathy?

Led by Dr. Maron, the panelists discussed early diagnosis of obstructive hypertrophic cardiomyopathy (oHCM), which is critical to prevent disease progression, reduce the risk of complications such as arrhythmias or sudden cardiac death, and guide appropriate management. Thorough history taking plays a key role in identifying symptoms, uncovering family history, and recognizing patterns that may otherwise be overlooked due to the nonspecific nature of presentation. Treatment recommendations for oHCM typically begin with pharmacologic therapy, such as beta-blockers or calcium channel blockers, to reduce symptoms and left ventricular outflow tract obstruction. For patients with persistent symptoms, additional options include novel agents like cardiac myosin inhibitors or invasive interventions such as septal reduction therapy to improve functional status and quality of life.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Our next episode, Monitoring Treatment Response and Advancing Therapy in Obstructive HCM, further explores strategies for monitoring patient response to pharmacologic therapy and post-procedural outcomes in obstructive hypertrophic cardiomyopathy, including symptom assessment and imaging. It also reviews key clinical trial data from EXPLORER-HCM and VALOR-HCM that supported the FDA approval of mavacamten, highlighting its safety and efficacy in improving patient outcomes.